Lower doses of bosentan in combination with sildenafil might be beneficial in pulmonary arterial hypertension

Lower doses of bosentan in combination with sildenafil might be beneficial in pulmonary arterial hypertension

Background: Endothelin-receptor-antagonist, bosentan, has been found to improve the functional capacity and cardiopulmonary hemodynamics in Pulmonary Arterial Hypertension (PAH). Clinical trials have shown the preferable dosage of 125 mg, twice daily, regarding both efficacy and safety. Objectives:...

Full description

Bibliographic Details
Main Authors: Ahmad Amin, Arezoo Mohamadifar, Sepideh Taghavi, Nasim Naderi, Hosnolah Sadeghi
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2015-01-01
Series:Research in Cardiovascular Medicine
Subjects:
Pulmonary Hypertension; Endothelin Receptor Antagonist; Bosentan; Chronic Thromboembolic Pulmonary Hypertension
Online Access:http://www.rcvmonline.com/article.asp?issn=2251-9572;year=2015;volume=4;issue=3;spage=7;epage=7;aulast=Amin;type=0

Internet

http://www.rcvmonline.com/article.asp?issn=2251-9572;year=2015;volume=4;issue=3;spage=7;epage=7;aulast=Amin;type=0

Similar Items